29 July 2019
Major Russian pharmaceutical company NovaMedica and the US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen®, a hormone secreted by the pineal gland in a 24-hour circadian rhythm, regulating the normal sleep/wake cycle. Production capacity expected to reach hundreds of thousands of packages per year. It will be enough to meet the requirements of patients living in the territory of the EAEU.
23 July 2019
The Russian pharmaceutical market is considered to be one of the most dynamic ones. In recent years, the annual growth is about 10%. The state policy that stimulates the production localization is effectively implemented. A new investment instrument has been launched in Russia – a special investment contract (SPIC). On March 7, 2018, NovaMediña, a portfolio company of RUSNANO, concluded the largest in the pharmaceutical industry a special investment contract (SPIC) with the Russian Federation represented by the Ministry of Industry and Trade of Russia and the Kaluga Region to establish the production of sterile injectable dosage forms.
19 June 2019
Russian drug companies NovaMedica and Pharmsynthez have launched a joint project to make a number of effective drugs available to Russian patients within 1.5-2 years. Integrated local production of these drugs will be set up in Russia, RUSNANO informed.
18 April 2019
Si quiere atraer a un socio internacional (proveedor) para localizar en su empresa sus productos, debe seguir con exactitudm las normas internacionales. Conocer y ser capaz de realizar transferencia correctamente. Al parecer, no hay de que discutir. Pero aun, prevalecen los antiguos enfoques en la organization de transferencia de tecnologias farmaceuticas: "Escribannos los componentes, y nosotros lo dominaremos todo aqui por nuestra cuenta".
11 February 2019
Der Mannheimer Industriedienstleister Bilfinger hat vom russischen Pharmaunternehmen Novamedica den Auftrag zur Lieferung einer Arzneimittel-Produktionsanlage erhalten. Das Projekt soll von Bilfinger Industrietechnik Salzburg abgewickelt werden und umfasst die Konstruktion und Errichtung von drei Ansatzsystemen zur Herstellung steriler Arzneiformen. Es ist der erste Auftrag für das Bilfinger-Tochterunternehmen Russland.
22 January 2019
For seven years past from its existence Kaluga Pharmaceutical Cluster has been dynamically developing significantly exceeding the growth rates in other economic sectors of the region. And the question is not only about opening of manufacturing facilities but also about further localization and extension of manufacturing capacity of already existing plants of both Russian and foreign manufacturers. 2018 was no exception. In March of 2018, NovaMedica LLC concluded a special investment contract (SPIC) with the Russian Ministry of Industry and Trade and Kaluga Region.
11 December 2018
NIBIB-funded researchers recently validated a rapid STD test that delivered accurate results in about 30 minutes for chlamydia, allowing patients to receive treatment immediately, thereby stemming the further spread of disease. Other analyses showed most women preferred the easy self-collection method the test offers.
07 November 2018
Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients. The Canadian centers include Mount Sinai Hospital's Marvelle Koffler Breast Centre, the Princess Margaret Cancer Centre, Sunnybrook Odette Cancer Centre, and BC Cancer.
09 October 2018
The international exhibition CPhI has started in Madrid. And today NovaMedica Innotech is in our focus as the company that has made a bright debut at the exhibition. This Technological Center has launched in April 2017 and Moscow Mayor Sergei Sobyanin attended the opening ceremony.
03 October 2018
The current model of the pharmaceutical business in the context of R&D in Russia reflects the world trends. One of the striking examples is R&D Center of NovaMedica Innotech. It belongs to the group of CDMO (contract development and manufacturing organizations), whose task is to provide services following the 'one contact’ principle: pharmaceutical development, technology development, technology transfer, and manufacturing of small batches of products - both for clinical trials and for manufacturing of finished products batches (based on the GMP license).
11 December 2019
11 December 2019
10 December 2019
10 December 2019